Evidence map›Paper›PMID 38747232›Full record

ReviewCurrent pharmaceutical design2024

Niosomes as a Promising Therapeutic Approach against Colorectal Cancer: A Focus on the Delivery of Chemotherapeutics and Natural Products.

Samaneh Mollazadeh, Abdulridha Mohammed Al-Asady, Amirhosein Barjasteh, Hanieh Latifi, Amir Avan, Majid Khazaei, Mikhail Ryzhikov, Seyed Mahdi Hassanian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Samaneh MollazadehNatural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Abdulridha Mohammed Al-AsadyDepartment of Medical Sciences, Faculty of Nursing, Warith Al-Anbiyaa University, Kerbala, Iraq.
Amirhosein BarjastehFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hanieh LatifiFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir AvanDepartment of Human Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mikhail RyzhikovSchool of Medicine, Saint Louis University, St. Louis, MO 63103, USA.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

Mashhad University of Medical Sciences 4000652
6 · The paper itself

Abstract

Nanotechnology has emerged as an effective approach to cancer treatment, including Colorectal Cancer (CRC). While conventional treatments, such as chemotherapeutic agents, are used to manage CRC, their efficacy can be improved using drug delivery systems that enhance their bioavailability and reduce side effects. Niosomes, polymeric nanoparticles, have shown promise as biocompatible vehicles that can transport hydrophilic and lipophilic molecules. This can result in reduced drug dosage and increased efficacy. This review examines the use of niosomal formulations as a delivery platform for treating CRC and provides practical insights into their clinical applications.

Indexed as

Antineoplastic AgentsBiological ProductsColorectal NeoplasmsDrug Delivery SystemsLiposomesAnimalsHumansNanoparticlesAntineoplastic AgentsBiological ProductsLiposomeschemotherapeuticsColorectal cancernanoparticlesnanotechnology.natural productsniosomes

Identifiers

PMID38747232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.